StockWatch
·

CRISIL LTD. Q2 FY27 Results

CRISILQ2 FY27 Results
Filing
Result:Steady· Market: Crashed#Margin squeeze

Beat/Miss: Miss

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue1.1K1.8%20.2%
Total Income1.1K2.2%18.2%
Expenditure844.863.5%23.2%
PBT276.051.4%5.3%
Net Profit204.545.5%5.9%
OPM27.53%1.10pp1.36pp
NPM18.25%1.49pp2.11pp
EPS27.975.5%5.9%
View full financials

PAT grew just 6% YoY on 20% revenue growth as NPM fell to 18.3% from 20.4% a year ago, driven by Research Analytics margin compression, missing the street's PAT estimate despite in-range revenue.

Q2 FY-2027 RESULTS · CRISIL

CRISIL Q2 FY27: Consolidated PAT +6% YoY as margins compress despite 20% revenue growth

PAT +6% YoY · revenue +20.2% · margins compressing · miss vs street

23 Oct 2026 · 3 min read
Revenue

₹1,095.16 Cr

+20.2% YoY

PAT (consolidated)

₹204.64 Cr

+6% YoY

Net margin

18.26%

-2.1pp YoY

EPS

₹27.97

CRISIL's consolidated PAT for Q2 FY27 (quarter ended 30 September 2026) came in at ₹204.64 Cr, up just 6.0% YoY from ₹193.10 Cr and down 5.5% QoQ from ₹216.46 Cr — a sharp divergence from revenue, which grew 20.2% YoY to ₹1,095.16 Cr (+1.8% QoQ). There are no exceptional items on either side of the comparison, so the YoY PAT growth is effectively as-reported and still only a fraction of the topline gain. Against our pre-result preview (revenue ₹1,070–1,100 Cr, PAT ₹210–225 Cr), revenue landed in-range but PAT missed the low end of the range, making this a street miss on earnings despite an inline top line.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹1,095.16 Cr+1.8%+20.2%
Expenses₹844.86 Cr+3.4%+23.2%
PAT₹204.64 Cr-5.5%+6%
Net margin18.26%-1.5pp-2.1pp
EPS₹27.97-5.5%+5.9%

The gap is a margin story. Consolidated NPM fell to 18.26% from 20.36% a year ago (19.74% last quarter) and OPM slipped to roughly 27.5% from 28.9% YoY. Segment data pins the compression on Research, Analytics & Solutions: its revenue grew only 16.5% YoY to ₹749.89 Cr — well short of the "high-20s%" pace the Street was watching for pre-result, and actually down 2.7% sequentially — while its segment margin fell to 17.25% from 21.9% a year ago and 20.4% last quarter. Ratings services was the opposite story: revenue grew 28.9% YoY to ₹345.63 Cr and segment profit rose 28.6% YoY to ₹155.19 Cr, holding a steady ~45% margin, confirming the post-merger integration of Bridge to India has not dented ratings economics. Cost lines outpaced revenue broadly: employee costs +20.3% YoY, professional fees +47.7% YoY, and D&A +38.3% YoY (the latter partly reflecting the Crisil Canada–Pricemetrix amalgamation completed 1 August 2026); other income also fell 30.4% YoY to ₹25.75 Cr, adding a further drag on consolidated PAT versus the operating story.

₹
4,163.244,345.524,527.84,710.084,892.364,750.107-2008-1109-0209-2510-2110-23Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹4,750.1, up 5.1% over the past month of trading.

₹ Cr
087.08174.17261.25171.57Q1 FY26rev ₹843 Cr193.1Q2 FY26rev ₹911 Cr153.42Q3 FY26rev ₹512 Cr233.26Q4 FY26rev ₹1,058 Cr216.46Q1 FY27rev ₹1,075 Cr204.64Q2 FY27rev ₹1,095 Cr
Quarterly consolidated PAT, ₹ Crore

For context: revenue is at a 6-quarter high.

Management issued no formal guidance or outlook commentary in this release (no press release text was available in the context, and none appears in our prior records), so there is no guidance line to grade the print against beyond Street consensus. The Board declared a third interim dividend of ₹17/share, well above the ₹10–12/share our preview had flagged, a signal of confidence that sits somewhat at odds with the margin softness. Standalone PAT was ₹151.94 Cr, up 10.6% YoY from ₹137.39 Cr, aided by ₹85 Cr of dividend income from subsidiaries booked in other income — standalone and consolidated tell different growth stories (10.6% vs 6.0% PAT growth) because the standalone number captures upstreamed dividends rather than the Research segment's operating drag, so neither figure should be read in isolation.

  • W1

    Research, Analytics & Solutions segment margin (17.25% this quarter vs 21.9% a year ago) — whether it stabilises or compresses further next quarter

  • W2

    Research segment revenue growth, which decelerated to 16.5% YoY from the high-20s% pace the Street was tracking pre-result

  • W3

    D&A run-rate (+38.3% YoY to ₹44.18 Cr), partly tied to the Crisil Canada-Pricemetrix amalgamation completed 1 August 2026 — watch for normalisation

Clean digital table, columns unambiguous (30-Sep-26 vs 30-Jun-26 vs 30-Sep-25 verified against context). Sub-cr rounding drift (~₹0.1 Cr) between stated PBT/PAT and recomputed totals is normal filing rounding, not an error. No exceptional items or minority interest line. Standalone other income includes ₹85 Cr dividend from subsidiaries (note 3). Two subsidiaries reviewed by component auditors per the review report, not a numbers flag.

Informational and educational content only. Not investment advice.